Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.

ABSTRACT:

Purpose

Ongoing angiogenesis renders the tumor endothelium unresponsive to inflammatory cytokines and interferes with adhesion of leukocytes, resulting in escape from immunity. This process is referred to as tumor endothelial cell anergy. We aimed to investigate whether anti-angiogenic agents can overcome endothelial cell anergy and provide pro-inflammatory conditions.

Experimental design

Tissues of renal cell carcinoma (RCC) patients treated with VEGF pathway-targeted drugs and control tissues were subject to RNAseq and immunohistochemical profiling of the leukocyte infiltrate. Analysis of adhesion molecule regulation in cultured endothelial cells, in a preclinical model and in human tissues was performed and correlated to leukocyte infiltration.

Results

It is shown

SUBMITTER: Nowak-Sliwinska P 

PROVIDER: S-EPMC10119234 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature